Cite as: 566 U. S. ____ (2012)

1

Opinion of the Court
NOTICE: This opinion is subject to formal revision before publication in the
preliminary print of the United States Reports. Readers are requested to
notify the Reporter of Decisions, Supreme Court of the United States, Washington, D. C. 20543, of any typographical or other formal errors, in order
that corrections may be made before the preliminary print goes to press.

SUPREME COURT OF THE UNITED STATES
_________________

No. 10–844
_________________

CARACO PHARMACEUTICAL LABORATORIES, LTD.,
ET AL., PETITIONERS v. NOVO NORDISK A/S ET AL.
ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF
APPEALS FOR THE FEDERAL CIRCUIT
[April 17, 2012]

JUSTICE KAGAN delivered the opinion of the Court.
When the Food and Drug Administration (FDA) evaluates an application to market a generic drug, it considers
whether the proposed drug would infringe a patent held
by the manufacturer of the brand-name version. To assess
that matter, the FDA requires brand manufacturers to
submit descriptions of the scope of their patents, known as
use codes. The FDA does not attempt to determine if that
information is accurate. Rather, the FDA assumes that
it is so and decides whether to approve a generic drug on
that basis. As a result, the breadth of the use code may
make the difference between approval and denial of a
generic company’s application.
In this case, we consider whether Congress has authorized a generic company to challenge a use code’s accuracy
by bringing a counterclaim against the brand manufacturer in a patent infringement suit. The relevant statute
provides that a generic company “may assert a counterclaim seeking an order requiring the [brand manufacturer] to correct or delete the patent information [it]
submitted . . . under [two statutory subsections] on the

